Cases of rare vulvar ulcers have been diagnosed in adolescent girls after receiving a second dose of the Pfizer messenger RNA (mRNA) shot, according to the April edition of the Journal of Pediatric & Adolescent Gynecology.
Six cases of adolescent girls ages 12 to 16 developing painful genital ulcers within four days of their second vaccine dose were reported in the medical journal, including two cases occurring after infection with COVID-19.
This is the first time that cases of vulvar ulcers in adolescents and young women are being addressed and discussed in the medical literature.
Doctors in these cases say it's “important to identify and explain possible adverse effects to help dispel the hesitancy some patients might feel about receiving a novel vaccine.”
The vulvar ulcers—known as vulvar aphthous ulcers, lipschütz ulcers, or acute genital ulcerations—are nonsexually acquired painful lesions formed on the external structures of the female genitalia, or the vulva. The condition mainly affects adolescents and young women, but cases of older women have also been reported.
Unlike mouth sores, which are an established adverse reaction of certain vaccines, including the COVID-19 injections administered in the United States, vulvar ulcers are not.
A simple search on the Vaccine Adverse Event Reporting System (VAERS) for aphthous ulcer, vaginal ulceration, vulval ulceration, and Pfizer COVID-19 vaccine, resulted in 282 total events as of April 14.
Of those, over 40 reports were related to genital ulcers in adolescents and young women several days after the second Pfizer shot, while the rest were reports of mouth ulcers. Several cases have also occurred following the first and third dose.
The youngest to experience the vulvar ulcers was a 10-year-old girl from North Carolina, who developed several painful lesions 24 hours after her second Pfizer injection on Jan. 29, 2022 (VAERS ID number: 2087752-1). She tested negative for the herpes simplex virus. The report didn't mention whether a COVID-19 test was administered.
The Centers for Disease Control and Prevention (CDC) cautions that reports made to VAERS don't necessarily prove causation.
Case ReportsThe first case report to describe a potential association between the development of vulvar ulcers and Pfizer COVID-19 vaccination was of a 16-year-old patient from Minnesota. She experienced fever, body pain, fatigue, and vaginal lesions within 24 hours of getting a second dose of the mRNA COVID-19 shot. The ulcers became extremely painful and the patient had difficulty with walking, urination, and defecation when she was seen at the pediatric gynecology clinic six days after her vaccination.
The patient was tested for COVID-19, sexually transmitted diseases, and two common viruses—Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Every test was negative except for the EBV test, which indicated she had a prior infection.
Nonsexually acquired vulvar ulcers have been associated with several viral infections, including EBV, influenza, and most recently, COVID-19. However, based on the patient’s clinical presentation, the doctors concluded that the ulcers were associated with the Pfizer mRNA vaccine.
With no standard treatment protocol for these types of ulcers, treatment usually involves administering oral and topical medications for pain control. Sitz baths are also prescribed to relieve pain, swelling, and other symptoms.
“We believe this case demonstrates a possible novel association between the Pfizer vaccine and development of a vulvar aphthous ulcer in an adolescent patient,” the authors of the report wrote.
“In this time of pandemic, testing for COVID-19 infection or inquiring about recent COVID-19 vaccination should be considered in all young women presenting with acute genital ulcerations,” the authors of the case report said.
All six patients had no adverse reaction to their first Pfizer injection. The time needed to resolve the ulcers and pain varied for each patient, ranging from one week to three weeks with medications and other supportive care.
Pfizer officials didn’t respond by press time to a request by The Epoch Times for comment.